Asciminib Pediatric formulation group + Asciminib Adult formulation group
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloid Leukemia, Philadelphia Positive
Conditions
Myeloid Leukemia, Philadelphia Positive
Trial Timeline
Dec 27, 2021 → Nov 1, 2031
NCT ID
NCT04925479About Asciminib Pediatric formulation group + Asciminib Adult formulation group
Asciminib Pediatric formulation group + Asciminib Adult formulation group is a phase 1/2 stage product being developed by Novartis for Myeloid Leukemia, Philadelphia Positive. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04925479. Target conditions include Myeloid Leukemia, Philadelphia Positive.
What happened to similar drugs?
10 of 20 similar drugs in Myeloid Leukemia, Philadelphia Positive were approved
Approved (10) Terminated (4) Active (8)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04925479 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Myeloid Leukemia, Philadelphia Positive